原发性子宫骨肉瘤的多学科治疗,包括基因组检测:病例报告和文献综述。

IF 0.5 Q4 ONCOLOGY International Cancer Conference Journal Pub Date : 2023-05-09 eCollection Date: 2023-10-01 DOI:10.1007/s13691-023-00613-x
Takako Kusanishi, Naotake Tanaka, Mizue Itoi, Miwa Ijiri, Keiko Ebisawa, Kiyomi Suzuka, Youko Hagiwara, Tukasa Yonemoto, Akinobu Araki, Makiko Itami
{"title":"原发性子宫骨肉瘤的多学科治疗,包括基因组检测:病例报告和文献综述。","authors":"Takako Kusanishi, Naotake Tanaka, Mizue Itoi, Miwa Ijiri, Keiko Ebisawa, Kiyomi Suzuka, Youko Hagiwara, Tukasa Yonemoto, Akinobu Araki, Makiko Itami","doi":"10.1007/s13691-023-00613-x","DOIUrl":null,"url":null,"abstract":"<p><p>Primary osteosarcoma of the uterus (uOS) is rare, and its standard treatment has not yet been established. Herein, we present the case of a 50-year-old woman with uOS who demonstrated an improved prognosis after multiple surgeries to the metastatic sites. After the initial diagnosis of uOS, the patient showed recurrence and distant metastasis and hence expected to exhibit a poor prognosis. The patient underwent multiple surgical resections of the metastatic as well as primary tumors, which enabled the patient to survive for 24 months after the initial surgery. Considering that the median survival time of patients with uOS is approximately 6 months, the survival rate of our patient is noteworthy. Based on our observations, it is suggested that the resection of the primary and metastatic tumors might contribute to the extension of the survival period of the patient with chemo-resistant uOS.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 4","pages":"241-247"},"PeriodicalIF":0.5000,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421837/pdf/","citationCount":"0","resultStr":"{\"title\":\"Multidisciplinary management for primary uterine osteosarcoma, including gene panel testing: case report and literature review.\",\"authors\":\"Takako Kusanishi, Naotake Tanaka, Mizue Itoi, Miwa Ijiri, Keiko Ebisawa, Kiyomi Suzuka, Youko Hagiwara, Tukasa Yonemoto, Akinobu Araki, Makiko Itami\",\"doi\":\"10.1007/s13691-023-00613-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Primary osteosarcoma of the uterus (uOS) is rare, and its standard treatment has not yet been established. Herein, we present the case of a 50-year-old woman with uOS who demonstrated an improved prognosis after multiple surgeries to the metastatic sites. After the initial diagnosis of uOS, the patient showed recurrence and distant metastasis and hence expected to exhibit a poor prognosis. The patient underwent multiple surgical resections of the metastatic as well as primary tumors, which enabled the patient to survive for 24 months after the initial surgery. Considering that the median survival time of patients with uOS is approximately 6 months, the survival rate of our patient is noteworthy. Based on our observations, it is suggested that the resection of the primary and metastatic tumors might contribute to the extension of the survival period of the patient with chemo-resistant uOS.</p>\",\"PeriodicalId\":13703,\"journal\":{\"name\":\"International Cancer Conference Journal\",\"volume\":\"12 4\",\"pages\":\"241-247\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2023-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421837/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Cancer Conference Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13691-023-00613-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-023-00613-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

原发性子宫骨肉瘤(uOS)是罕见的,其标准治疗方法尚未确定。在此,我们介绍了一例50岁的uOS妇女,她在对转移部位进行多次手术后,预后有所改善。在最初诊断为uOS后,患者出现复发和远处转移,因此预计预后不佳。患者接受了多次转移性和原发性肿瘤的手术切除,这使患者能够在初次手术后存活24个月。考虑到uOS患者的中位生存时间约为6个月,我们患者的生存率值得注意。根据我们的观察,原发性和转移性肿瘤的切除可能有助于延长化疗耐药uOS患者的生存期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Multidisciplinary management for primary uterine osteosarcoma, including gene panel testing: case report and literature review.

Primary osteosarcoma of the uterus (uOS) is rare, and its standard treatment has not yet been established. Herein, we present the case of a 50-year-old woman with uOS who demonstrated an improved prognosis after multiple surgeries to the metastatic sites. After the initial diagnosis of uOS, the patient showed recurrence and distant metastasis and hence expected to exhibit a poor prognosis. The patient underwent multiple surgical resections of the metastatic as well as primary tumors, which enabled the patient to survive for 24 months after the initial surgery. Considering that the median survival time of patients with uOS is approximately 6 months, the survival rate of our patient is noteworthy. Based on our observations, it is suggested that the resection of the primary and metastatic tumors might contribute to the extension of the survival period of the patient with chemo-resistant uOS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
14.30%
发文量
57
期刊介绍: This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)
期刊最新文献
HER2-targeted therapy is changing. A case of gastritis caused by immune checkpoint inhibitor treated with infliximab. A case of grade1 follicular lymphoma diagnosed by laparoscopic lymph node resection: differentiating from late lymph node recurrence of endometrial cancer. A case report of mucinous borderline ovarian tumor with recurrence as invasive carcinoma with high copy number alterations. SMARCA4-deficient uterine tumors in young women: response to immune checkpoint inhibitors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1